文献速递心脑血管急症

常规医疗中替格瑞洛与普拉格雷治疗急性冠脉综合征的比较

Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care.
PubMed 文献 · JAMA Netw Open · 2024-12-02
一句话结论德国索赔数据库模拟ISAR-REACT5显示,ACS侵入性治疗后出院患者中普拉格雷较替格瑞洛1年死亡、心梗或卒中复合终点更低(HR 1.24)。

该研究利用德国法定医保索赔数据库(2012年1月至2021年12月),采用1:1倾向评分最近邻匹配模拟ISAR-REACT5,纳入出院后接受替格瑞洛或普拉格雷处方的ACS患者并随访1年。共匹配17642例(平均年龄63.1岁,73.9%男性),替格瑞洛组与普拉格雷组各8821例。主要复合终点(全因死亡、心梗或卒中)替格瑞洛组815例(9.2%)vs 普拉格雷组663例(7.5%),HR 1.24(95%CI 1.12-1.37);心梗(HR 1.20)和卒中(HR 1.33)在替格瑞洛组显著更多,全因死亡、支架血栓和大出血无显著差异。作者认为在常规医疗侵入性治疗的ACS患者中,普拉格雷与较低的复合终点相关,尤其在STEMI患者中。

要点

  • 匹配后替格瑞洛组主要复合终点(全因死亡、心梗或卒中)9.2%(815例)vs 普拉格雷组7.5%(663例),HR 1.24(95%CI 1.12-1.37)。
  • 心梗在替格瑞洛组显著更多(HR 1.20;95%CI 1.06-1.36),卒中亦显著更多(HR 1.33;95%CI 1.02-1.74)。
  • 全因死亡(HR 1.27;95%CI 0.99-1.64)、支架血栓(HR 1.11;95%CI 0.89-1.30)和大出血(HR 1.12;95%CI 0.96-1.32)两组无显著差异。
  • 亚组分析显示STEMI患者中普拉格雷组主要复合终点事件更少:338/4941(6.8%)vs 451/4852(9.3%)。
  • 与ISAR-REACT5比较,12项预设一致性指标中11项达成一致。

适用人群与场景

  • 德国法定医保索赔数据库中的ACS患者,出院后接受替格瑞洛或普拉格雷门诊处方,计划接受侵入性治疗策略,年龄≥18岁且有心血管危险因素,随访1年。

诊断标准与关键阈值

  • 纳入标准紧密模拟ISAR-REACT5,包括年龄≥18岁和心血管危险因素。
  • 采用1:1倾向评分最近邻匹配。

研究设计与关键结果

  • 研究类型:新使用者队列研究,使用德国法定医保索赔数据库2012年1月至2021年12月二次数据,1:1倾向评分最近邻匹配模拟ISAR-REACT5。
  • 人群与样本量:匹配后17642例(平均[SD]年龄63.1[10.9]岁;73.9%男性),替格瑞洛组8821例,普拉格雷组8821例。
  • 主要终点:1年内全因死亡、心梗或卒中复合终点,替格瑞洛组815例(9.2%)vs 普拉格雷组663例(7.5%),HR 1.24(95%CI 1.12-1.37)。
  • 次要终点:心梗HR 1.20(95%CI 1.06-1.36),卒中HR 1.33(95%CI 1.02-1.74),均在替格瑞洛组显著更多;全因死亡HR 1.27(95%CI 0.99-1.64)无显著差异;支架血栓HR 1.11(95%CI 0.89-1.30)无显著差异。
  • 安全性终点:大出血HR 1.12(95%CI 0.96-1.32),两组无显著差异。
  • 亚组分析:STEMI患者中主要复合终点普拉格雷组338/4941(6.8%)vs 替格瑞洛组451/4852(9.3%)。
  • 与ISAR-REACT5比较,12项预设一致性指标中11项达成一致。

证据类型、等级与局限

  • 证据类型:基于德国法定医保索赔数据库的新使用者队列研究,采用倾向评分匹配模拟随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在常规医疗中接受侵入性治疗策略的ACS患者,普拉格雷与较替格瑞洛更低的全因死亡、心梗或卒中发生率相关,尤其在STEMI患者中。
  • 作者认为,精心设计的数据库研究可以补充和扩展随机临床试验的结果,为指南和临床决策提供信息。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In patients with acute coronary syndrome (ACS) undergoing invasive treatment, ticagrelor and prasugrel are guideline-recommended P2Y12 receptor inhibitors. The ISAR-REACT5 randomized clinical trial demonstrated superiority for prasugrel, although concerns were raised about the generalizability of some underpowered subgroup analyses.

OBJECTIVES: To emulate a randomized clinical trial evaluating the safety and effectiveness of ticagrelor vs prasugrel under the conditions of routine care in individuals with ACS planned to undergo an invasive treatment strategy.

DESIGN, SETTING, AND PARTICIPANTS: This new-user cohort study included secondary data from a German statutory health insurance claims database between January 2012 and December 2021, using 1:1 propensity score nearest-neighbor matching to emulate ISAR-REACT5. Individuals with ACS receiving either ticagrelor or prasugrel treatment after hospital discharge were followed up for 1 year. Eligibility criteria closely emulated those of ISAR-REACT5 and included age of 18 years or older and cardiovascular risk factors. Data were analyzed from May 2023 to May 2024.

EXPOSURE: Outpatient prescription of ticagrelor or prasugrel.

MAIN OUTCOMES AND MEASURES: The primary end point was the composite of all-cause mortality, myocardial infarction (MI), or stroke within 1 year of outpatient treatment initiation. Secondary end points included individual components of the primary end point and stent thrombosis. The safety end point was major bleeding. A Cox proportional hazards regression model was fitted to the overall cohort.

RESULTS: Of 17 642 propensity score-matched individuals (mean [SD] age, 63.1 [10.9] years; 73.9% male), 8821 received ticagrelor and 8821 received prasugrel. Agreement was met in 11 of 12 predefined agreement metrics when comparing the results with ISAR-REACT5. The primary composite end point of all-cause mortality, MI, or stroke occurred in 815 individuals (9.2%) receiving ticagrelor and 663 (7.5%) receiving prasugrel (hazard ratio [HR], 1.24; 95% CI, 1.12-1.37). Myocardial infarction (HR, 1.20; 95% CI, 1.06-1.36) and stroke (HR, 1.33; 95% CI, 1.02-1.74) each occurred significantly more often in the ticagrelor group. Analysis of all-cause mortality (HR, 1.27; 95% CI, 0.99-1.64), stent thrombosis (HR, 1.11; 95% CI, 0.89-1.30), and major bleeding (HR, 1.12; 95% CI, 0.96-1.32) revealed no significant differences between treatment groups. Subgroup analysis showed that prasugrel was associated with the primary composite end point in fewer individuals with ST-segment elevation MI (338 of 4941 [6.8%] vs 451 of 4852 [9.3%]).

CONCLUSIONS AND RELEVANCE: This cohort study found that prasugrel was associated with lower rates of all-cause mortality, MI, or stroke compared with ticagrelor in individuals with ACS undergoing an invasive treatment strategy in routine care, particularly in individuals with ST-segment elevation MI. The findings suggest that carefully designed database studies can complement and extend findings from randomized clinical trials, informing guidelines and clinical decision-making.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Krüger N, Krefting J, Kessler T, et al. Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care. JAMA Netw Open. 2024. PMID: 39621344. doi:10.1001/jamanetworkopen.2024.48389

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。